Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY2AEF)

• Drug Name: PAI-1 Drug Info
• Synonyms: PA Autoinducer; Pseudomonas aeruginosa autoinducer; N-(3-Oxododecanoyl)homoserine lactone; 3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)dodecanamide; 152833-54-0; CHEBI:29639; 3-oxo-N-(2-oxotetrahydrofuran-3-yl)dodecanamide; N-(3-ketododecanoyl)homoserine lactone; 3-oxo-C12-AHL; 3-oxo-N-(2-oxooxolan-3-yl)dodecanamide; AC1L2SRN; CHEMBL482476; SCHEMBL10076544; BCP19350; AN-30880; RT-014202; 3-(3-Oxododecanoylamino)tetrahydrofuran-2-one; C11840; Dodecanamide, 3-oxo-N-(tetrahydro-2-oxo-3-furanyl)-
• Cross-matching ID:
  PubChem CID: 3246941
  ChEBI ID: CHEBI:44534
  CAS Number: CAS 168982-69-2
  TTD Drug ID: DMY2AEF

Molecule-Related Drug Atlas

Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pro-urokinase	DMGKT2L	Thrombin deficiency	3B14.Z	Approved	[4]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[5]
Amediplase	DM4FPM3	Myocardial infarction	BA41-BA43	Phase 3	[6]
Upamostat	DMFZULI	Breast cancer	2C60-2C65	Phase 2	[7]
Saruplase	DM1M0PR	Thrombosis	DB61-GB90	Phase 2	[8]
HTU-PA	DMNHE43	Cerebrovascular ischaemia	8B1Z	Phase 1/2	[9]
PMID18163548C4	DMHPME3	Myocardial ischemia	BA6Z	Clinical trial	[10]
UK-356202	DMSRK2A	Myocardial hypertrophy	BC45	Clinical trial	[11]
PAI-2	DMRSMW8	N. A.	N. A.	Discontinued in Phase 2	[12]
WX-UK1	DM8Q2ZR	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[13]

Drug(s) Affected By P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[14]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[15]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[16]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[17]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[18]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[19]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[22]

Drug(s) Affected By P2Y purinoceptor 4 (P2RY4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[24]

Drug(s) Affected By Serum paraoxonase/arylesterase 2 (PON2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[25]
Selenium	DM25CGV	N. A.	N. A.	Approved	[26]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[27]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[28]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[30]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[31]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[19]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Urokinase-type plasminogen activator (PLAU)	TTGY7WI	UROK_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
P2Y purinoceptor 2 (P2RY2)	OT47XN46	P2RY2_HUMAN	Gene/Protein Processing	[2]
P2Y purinoceptor 4 (P2RY4)	OTCYCROR	P2RY4_HUMAN	Gene/Protein Processing	[2]
Serum paraoxonase/arylesterase 2 (PON2)	OT55NCTD	PON2_HUMAN	Drug Response	[3]

References

• [1] Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
• [2] Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits expression of P2Y receptors in cystic fibrosis tracheal gland cells. Infect Immun. 1999 Oct;67(10):5076-82. doi: 10.1128/IAI.67.10.5076-5082.1999.
• [3] Paraoxonase 2 serves a proapopotic function in mouse and human cells in response to the Pseudomonas aeruginosa quorum-sensing molecule N-(3-Oxododecanoyl)-homoserine lactone. J Biol Chem. 2015 Mar 13;290(11):7247-58. doi: 10.1074/jbc.M114.620039. Epub 2015 Jan 27.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [7] Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
• [8] Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
• [9] Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
• [10] Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
• [11] Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
• [12] Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.
• [13] Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24.
• [14] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [15] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [16] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [17] Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2355-63.
• [18] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [19] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [20] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [21] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [22] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [23] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [24] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [25] Paraoxonase enzyme protects retinal pigment epithelium from chlorpyrifos insult. PLoS One. 2014 Jun 30;9(6):e101380. doi: 10.1371/journal.pone.0101380. eCollection 2014.
• [26] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [27] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [28] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [29] Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
• [30] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [31] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [32] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.